PRAGUE MEDICAL REPORT, Vol 124 No 4 (2023), 444–448
Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient
Eliška Dvořáčková, Andrea Zajacová, Jan Havlín, Eva Klapková, Robert Lischke, Ondřej Slanař, Martin Šíma
DOI: https://doi.org/10.14712/23362936.2023.34
zveřejněno: 09. 12. 2023
Abstract
Mucormycosis is a rare invasive fungal disease diagnosed in immunocompromised patients, including those with diabetes or iron overload, and in patients treated for hematological malignancies or after transplantation. Isavuconazole is a triazole antifungal effective against Mucorales with good tolerability, but with potential for relatively high interindividual variability in pharmacokinetics. This report demonstrates the case of a lung transplant recipient treated with isavuconasole that exhibits a very long elimination half-life of 159 hours, and discusses the practical implications of this finding for dosage adjustment and need for therapeutic drug monitoring.
klíčová slova: Isavuconazole; Antifungals; Pharmacokinetics; Therapeutic drug monitoring; Lung transplant recipient
Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient is licensed under a Creative Commons Attribution 4.0 International License.
167 x 240 mm
vychází: 4 x ročně
cena tištěného čísla: 450 Kč
ISSN: 1214-6994
E-ISSN: 2336-2936
